Patent NumberUS20210183053
|
Patent TitleHigh throughput method for accurate prediction of compound-induced liver injury
|
Abstract A method and system for predicting liver injury in vivo due to hepatocyte damage by a test compound are provided. The method includes acquiring images of fluorescently stained cells obtained from a cell culture in which the cells have been treated with a dose-range of at least the test compound and its vehicle. The cells may be hepatic cells including primary or immortalized hepatocytes, hepatoma cells or induced pluripotent stem cell-derived hepatocyte-like cells. The acquired images are segmented. The method further includes extracting and analyzing one or more phenotypic features from the segmented images, wherein the one or more phenotypic features are selected from the group of intensity, textural, morphological, or ratiometric features consisting of (a) features of DNA, (b) features of RELA (NF-KB p65), and (c) features of actin filaments at different subcellular regions and d) features of cellular organelles and their substructures in the segmented images. Finally, the method includes normalizing results from the treated samples to vehicle controls and predicting the probability of liver injury by the test compound based on test compound-induced normalized changes of the extracted and selected phenotypic features using machine learning methods.
|
Patent NumberUS11249081
|
Patent TitleMethods for the identification, targeting and isolation of human dendritic cell (DC) precursors (pre-DC) and their uses thereof
|
Abstract Biomarkers for the detection and identification of a precursor of conventional dendritic cell (cDC) (pre-DC) and its cell subsets (pre-cDC1 or pre-cDC2), are defined, which include CD169, CD327, AXL, CD271, CD324 and combinations thereof for detecting pre-DCs. Methods for detecting a disease or condition, prognosis of an existing disease or condition comprising determining the number of pre-DC cells in sample from a subject as compared to control, as well as methods of treating a patient comprising administration of antibodies against CD169, CD327, AXL, CD271, CD324 and combinations thereof are also disclosed. In addition, an immunogenic composition comprising one or more binding molecules specific for one or more biomarkers or antigen of a target disease and/or one or more cells selected from the group consisting of early pre-DC, pre-cDC1 and pre-cDC2 are also disclosed for eliciting an immune response against an infectious disease or cancer.
|
Patent NumberUS11248106
|
Patent TitleMethod of forming an exfoliated or intercalated filler material
|
Abstract According to the present disclosure, a method of forming an exfoliated or intercalated filler material is provided, wherein the said method comprises the steps of mixing particles of filler material such as montmorillonite (MMT), mica, layered double hydroxide (LDH), and attapulgite (AT) dispersed in an aqueous medium with cationic acrylate monomers to form modified particles comprising positively charged ions, dispersing the modified particles in organic medium to form a dispersion, contacting said dispersion with an organo-silicate such as tetraethyl orthosilicate (TEOS) and a functionalizing agent comprising an organo-silane such as aminopropyltrimethoxysilane (APTMS), in the presence of a basic catalyst to form a layer of silica on the modified particles. The present disclosure also relates to an exfoliated or intercalated filler material obtained by the said method as well as a method of forming a resin/clay nanocomposite.
|
Patent NumberUS11242565
|
Patent TitleMultigene assay
|
Abstract An in vitro method of determining the type of a fibroepithelial tumour of the breast in a biological sample is provided. The method comprises the steps of obtaining an expression profile of one or more genes selected from the group consisting of PRAME, ADH1 B, CTHRC1, NPTX2, NEFL, ABCA8, DAPL1, TP63_v2, COL17A1, GCNT2, CCL19, MMP3, FN1, TRERF1, TRIM29, TESC, KIF20A, UHRF1, HEPACAM2, APOD, SERHL2. KIF15, HOXD13, GAGE2B, CALML5, C2orf40, ADH1C, CYP1B1, SPAG11B, GRB7, UBE2C, SYNGAP1, TP63_v1, LAMB1, OR5P3, SPC25, SHISA2, SCARA5, LHX2, RORC, DPYSL4, CH25H, and CHST1 in a sample and determining the differential activity of the one or more genes relative to a control; correlating the differential activity of the one or more genes relative to the control to obtain a p-score; and determining the type of fibroepithelial tumour based on the p-score, wherein a p-score of less than 0.5 is indicative of a fibroadenoma and a p-score of 0.5 and above is indicative of phyllodes tumour. Particularly, the said method is exemplified using an expression profile of five genes comprising of PRAME, FN1, CCL19, ABCA8 and APOD. A method for managing the treatment of a subject with a fibroepithelial tumour of the breast is also provided as well as a kit when used in the methods of the present invention.
|